03/07/2017 13th Congress of the EADO

13th Congress of the EADO  
 
31,872 total
757 video
1,363 photo
Views:
Please enter your username and password to access the webcasts of the 13th Congress of the EADO.
 
Forgot your password?

Welcome to the webcasts of the 13th Congress of the EADO.
Access to the videos is permitted to the registered delegates of the 13th Congress of the EADO and to the members of the EADO association. To access the webcasts you need to enter your username and password as provided to you by the congress secretariat.

For any questions please contact us at info@eado2017.org

To become a member of the EADO association and access the webcasts please click here
Enjoy!

C. Garbe - Melanoma - New Developments 35
C.Hoeller: PD-1 and CLT-4: Upfront or sequentially? 11
D.Schandendorf: How long checkpoint inhibition... 11
G.Long: Choice of immunotherapy versus targeted... 23
P.Lorigan: Update on mucosal & uveal melanoma 17
A. Hauschild: Targeted therapy in NRAS-mutated... 08
C. Lebbe: Immunotherapy in Merkel cell carcinoma 09
A. Stratigos: Opening Ceremony Lecture 12
C. Garbe: Does primary prevention of skin... 12
A.M. Forsea: Current standards in skin cancer... 09
P. Mohr: Lessons from the German skin cancer... 10
A. Sober: Skin cancer screening in the United... 06
V. del Marmol: Screening and prevention of... 09
I. Zalaudek: Dermoscopy and the evolution... 09
J. Malvehy: Dermoscopic overview of melanoma 12
A. Lallas: The morphologic universe of basal... 10
D. Sgouros: The spectrum of keratinocyte... 06
E. Lazaridou: Facial pigmented lesions 07
A. Katoulis: Spitzoid lesions 05
S. Puig: Dermoscopy and molecular biology 07
V. del Marmol: Novel risk associations of... 11
J.J. Grob: Fast growing melanoma: Do they... 07
S. Gandini: Vitamin D and melanoma - an open... 04
D. Whiteman: The pathways to cutaneous melanoma 09
N. Hayward: Novel high risk genes of melanoma 07
E. Soura: Genetic markers of prognostic outcome 13
S. Puig: Genetic testing in daily clinical... 07
D.E. Fisher: Pathways of melanoma development:... 06
D. Whiteman: The epidemiology of melanoma:... 09
J. Malvehy: New imaging approaches for the... 08
R. Kaufmann: Current standards of surgical... 05
A.Testori: Evidence-based assessment of SLN... 07
V. Sondak: The role of the surgeon in the... 05
J. Gershenwald: SNL beyond melanoma: Clinical... 07
H.Gogas: Updates in adjuvant melanoma trials 17
A. Hauschild: Kinase inhibitors in the adjuvant... 08
H. Gogas: 2017 state of the art for adjuvant... 05
L. Kandolf-Sekulovic: Access to innovative... 05
R. Giuliani: ESMO EU policy Committee initiatives... 05
B. Ryll: Melanoma Patient network Europe... 05
A. Roediger: EFPIA initiatives for improved... 03
T. Dirschka: Do we need a new classification... 08
G. Gupta: Topical therapy for actinic keratoses:... 07
E. Sotiriou: PDT for actinic keratoses: daylight... 09
S. Ribero: Regression in melanoma: From diagnosis... 06
K. Frangia - Tsivou: Tumor infiltrating cells... 05
V. Bataille: Genetics of melanocytic nevi 06
I. Stefanaki: Nevi monitoring: what's new? 04
Z. Apalla: Melanoma and pregnancy 09
P. Arenberger: Current need of early diagnosis... 04
D. Rigopoulos: Melanoma of the nail unit 05
C. Harwood: Melanoma in the immunosuppressed... 04
A. Stratigos: Update on systemic treatment... 09
D. Schadendorf: Checkpoint blockade in NMSC 09
R. Kunstfeld: Systemic treatment of BCC:... 06
D. Schadendorf: Clinical update on approved... 11
C. Hoeller: Monitoring response to targeted... 05
C. Robert: Resistance mechanisms to kinase... 03
R. Dummer: New candidate therapeutic targets 06
H. Linardou: Managing adverse reactions to... 04
J. Gershenwald: The new (8th edition) ΑJCC... 15
G. Long: The evolving therapeutic landscape... 11
P. Nghiem: Merkel cell carcinoma: new insights... 04
C. Blank: Update in anti-CTLA1 and anti-PD1... 03
C. Robert: Overcoming lack of response to... 05
S. Agarwala: Targeted therapy and immunotherapy... 01
D. Bafaloukos: Open questions in immunotherapy... 08
C. Garbe: Molecular testing for targeted... 03
O. Michielin: Combining checkpoint inhibitors 03
P. Ascierto: Combining immune checkpoint... 03
R. Dummer: Combination of systemic with intralesional... 04
A. Patsatsi: Classic cutaneous adverse reactions... 04
C. Lebbe: Cutaneous reactions to anti- EGFR... 03
V. Sibaud: Cutaneous reactions to immune... 03
E.Livingstone: Cutaneous reactions to BRAF/MEK... 03
S.Agarwala: Intralesionaltvec and combinations 02
A.Testori: Electrochemotherapy 02
O.Zoras: Isolated limb perfusion: Is it still... 03
N.Rompoti: Lesional chemotherapy and cytokines 03
O.Michielin: How does our surveillance algorithm... 03
P.Saiag: Serologic markers with predictive... 02
E.Lianidou: Circulating tumor cells in melanoma 07
A.Laskarakis: Brain metastases: Epidemiology... 03
F.Meier: Melanoma Brain Metastases: the targeted... 06
P.Mohr: Brain Metastases of Melanoma: Is... 01
JJ.Grob: Brain metastases of melanoma: Gamma-Knife... 04
E.Stockfleth: Updates on the biology and... 06
JT.Lear: How to Define High Risk BCC and... 05
R.M.Szeimies: Conventional and Daylight-PDT 03
K.Peris: Hedgehog inhibitors in advanced... 03
P.Saiag: Diagnosis and Treatment Dermatofibrosarcoma... 03
J.Olah: Cutaneous Sarcomas 05
A.Befon: Malignant Adnexal Tumors 04
C.Garbe: Challenges for Dermato-Oncology 05
J.Malvehy - S.Puigj: Interactive Cases 06
A.Lallas: Interactive Cases 05
Z.Apalla: Interactive Cases 04
G.Evangelou: Interactive Cases 04
D.Sgouros_ Interactive Cases 05
D.Papakostas: Interactive Cases 03
R.Vieira: An update on surgery and Mohs for... 05
D.Ntasiou-Plakida: Reconstructive Surgery... 02
A.Kalampokas: Making Surgical Complications... 02
T.Anthopoulos: Reconstructive Surgery for... 02
P.Polyzois: Combined Curettage and Cryosurgery... 02
P.Quaglino: Classification of cutaneous lymphomas:... 09
J.Scarisbrick: Prognostic Factors in Mycosis... 02
M.Vermeer: Diagnostic approach in CD30 Cutaneous... 02
R.Willemze:Folliculotropic Mycosis Fungoides(FMF):... 04
V.Nikolaou_Lymphoid Infiltrates 06
E.Papadavid: Treatment of early stage Mycosis... 05
R.Stadler:Treatment of latest agemf 08
M.Siakantaris: Treatment of Cutaneous bcell... 02
Pablo Ortiz Romero:New treatment for my Cosisfungoides 06
Supported by Roche - Industry Satellite Symposium... 14
Supported by Merck Pfizer Alliance - Industry... 07
Supported by Takeda - Industry Satellite... 04
E. Nagore: Epidemiologic trends of melanoma... 03
A. Geller: Melanoma and skin cancer screening:... 01